Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries OKYO Pharma Limited - Ordinary Shares (NQ: OKYO ) 1.030 +0.030 (+3.00%) Streaming Delayed Price Updated: 3:59 PM EDT, Oct 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about OKYO Pharma Limited - Ordinary Shares < Previous 1 2 3 Next > OKYO Pharma Announces Chairman Acquires Shares September 10, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Announces Chairman Acquires Shares September 05, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease August 27, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma CEO Interview to Air on Bloomberg TV August 23, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Announces Chairman Acquires Shares August 23, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV August 23, 2024 Via ACCESSWIRE OKYO Pharma Announces Chairman Acquires Shares August 21, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference August 15, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use August 06, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101 July 11, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease July 10, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Announces Participation in May 2024 Investor Conferences May 08, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO) April 30, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 April 08, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery April 02, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101 March 22, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial March 21, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event March 20, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain February 09, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board January 31, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease January 08, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024 January 05, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit December 04, 2023 Top-line Efficacy and Safety Data on Track for Release in December 2023 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction October 31, 2023 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”) October 09, 2023 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED") October 05, 2023 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma’s Advancing Clinical Mission to Better Treat Eye Disease Sends Shares 89% Higher Since August ($OKYO) October 05, 2023 Via AB Newswire OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares September 15, 2023 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares September 14, 2023 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Limited Announces Withdrawal of Public Offering September 14, 2023 From OKYO Pharma LTD Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.